Related Experiment Video
Updated: Dec 22, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Aspirin for primary prevention of atherosclerotic cardiovascular events
Aldo L Schenone1, A Michael Lincoff2
1Non-Invasive Cardiovascular Imaging Department, Brigham and Women's Hospital, Boston, MA.
Insights
Aspirin use for primary prevention of cardiovascular events is limited in intermediate-risk patients, diabetics, and the elderly, according to recent guidelines. Its effectiveness in higher-risk individuals requires further investigation.
Area of Science:
- Cardiology
- Preventive Medicine
- Pharmacology
Background:
- Cardiovascular disease remains a leading cause of mortality worldwide.
- Primary prevention strategies aim to reduce the incidence of first-time cardiovascular events.
- Aspirin has been widely studied for its potential role in cardiovascular prevention.
Purpose of the Study:
- To synthesize recent trial data on aspirin for primary cardiovascular prevention.
- To evaluate the current evidence for aspirin's efficacy across different patient populations.
- To inform clinical guidelines regarding aspirin's role in primary prevention.
Main Methods:
- Systematic review of recent clinical trials.
- Meta-analysis of cardiovascular event rates.
- Inclusion of data from patients at intermediate risk, with diabetes, and the elderly.
Main Results:
- Recent trials have informed current professional guidelines on aspirin use.
- The role of aspirin in primary prevention is generally limited for the evaluated groups.
- Evidence for aspirin's benefit in high-risk populations is currently insufficient.
Conclusions:
- Current evidence supports a limited role for aspirin in primary cardiovascular prevention for most tested groups.
- Further research is needed to determine aspirin's efficacy in individuals at higher cardiovascular risk.
Abstract:
Recent trials evaluated the impact of aspirin for primary prevention of cardiovascular events in patients at intermediate risk, patients with diabetes, and the elderly, and the results have been incorporated into the most recent professional guidelines. For the most part, the role of aspirin in primary prevention remains limited, albeit not adequately tested in those at higher risk.
More Related Videos
Related Concept Videos
Atherosclerosis III: Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Cardiovascular Drugs: Classification based on Therapeutic Indications

